Send PM
Followers 123
Posts 2504
Boards Moderated 0
Alias Born 11/03/2014

Re: None

Wednesday, 11/23/2022 3:45:58 PM

Wednesday, November 23, 2022 3:45:58 PM

Post# of 540006
The DCVax-L Phase III clinical trial results, for both newly diagnosed GBM (nGBM) and recurrent GBM (rGBM) were exceptional. What does the 13% long-tail overall survival (OS) numbers for newly diagnosed GBM patients mean is real-life? Also, what does the significant increase in the number of nGBM patients in the DCVax-L trial living 24, 36, and 48 months OS mean in real-life?

In the US there are about 13,000 patients per year diagnosed with nGBM. In the EU there are about 22,000 patients per year diagnosed with nGBM. In Canada, 3,000 patients per year diagnosed with nGBM. The total annual nGBM patients in all 4 regions where NWBio conducted the DCVax-L clinical trial is 38,000 nGBM patients per year. I have included some link sbelow to validate these numbers for each region.

These are real people, with real lives, families and loved ones. In the DCVax-L Phase III, 13% of all nGBM treated with DCVax-L were effectively cured (5+ years of complete remission). Based on the annual total number of nGBM patients in the US, UK, Canada, Germany and the rest of the EU, of approximately 38,000 nGBM patients, DCVax-L could effectively cure (5+ years of complete remission) about: 38,000 X 13% = 4,950 potentially cured nGBM patients per year..

In addition to the 13% of nGBM patients that are effectively cured, tens of thousands of the remaining nGBM will experience extended overall survival. The average overall survival for nGBM treated with the current standard of care (tumor resection + chemo + radiotherapy) is 14 to 16 months. More GBM patients in the DCVax-L Phase III trial experienced higher OS to 24, 36 and 48 months, compared to only 14 to 16 months. Every single day of extended life is precious for all GBM patients and their families.

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Recent NWBO News

FEATURED Goldshore Intersects Additional High-Grade Shears in the QES Zone at the Moss Lake Gold Project Nov 28, 2022 8:39 AM


Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM

Branded Legacy, Inc. Gets Approval From State to Reduce Authorized Common Shares by 300 Million BLEG Nov 22, 2022 1:15 PM

Defiance Resumes Drilling In Zacatecas DNCVF Nov 22, 2022 11:53 AM

InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of OTC Hearing Aids on INND Nov 22, 2022 11:52 AM

ECRID Offers Federal Housing Finance Agency (FHFA) Credit & Lending Platform to Immediately Assist Low-Credit and No-Credit Home Buyers, and Others ECDD Nov 22, 2022 11:51 AM

BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype BLFE Nov 22, 2022 11:50 AM

Fission 3.0 Hits Off-Scale Radioactivity in New Discovery on PLN A1 Conductor FUU Nov 21, 2022 11:05 AM

Perpetual Industries Reports Strong Third-Quarter PRPI Nov 21, 2022 8:00 AM

Nextech AR Solutions Corp. Reports Record Q3 Sequential Growth As 3D Modeling Revenue Surges +192% and Gross Profit Margin Improves To +60% NEXCF Nov 17, 2022 7:03 PM

AgriFORCE Receives Notice of Allowance Related to its FORCEGH+ Facility from the United States Patent and Trademark Office AGRIW Nov 17, 2022 9:06 AM

Organicell Starts Enrolling Long COVID Trial OCEL Nov 17, 2022 8:38 AM

Mullen Announces Funding to Close on ELMS Assets MULN Nov 17, 2022 8:30 AM